Fig. 4.

Overexpression of miR-650 ameliorates AD pathogenesis in APP/PSEN1 transgenic mice. A–B Immunohistochemistry of beta-amyloid for hippocampal sections from AAV-GFP control mice (A) and AAV-miR-650 mice (B). C AAV-miR-650 brain sections show significantly fewer number of plaques. D AAV-miR-650 mice show significantly lower amyloid-β (Aβ) levels (n = 3, unpaired t-test, p < 0.05). E–J Immunostaining of hippocampal sections for AAV-GFP control mice (E–G) and AAV-miR-650 mice (H–J). Neurons are indicated by red staining with MAP2 antibody. Arrow indicates increased neuronal staining in the presence of miR-650 overexpression. K AAV-miR-650 mice show significantly increased number of neuronal cells (n = 3, unpaired t-test, p < 0.05)